Is Royalty Pharma financially healthy?
Not really
Royalty Pharma carries heavy debt: it would take 5.1 years of earnings to pay it off.
The numbers behind it
Net debt / EBITDA5.1 years
Cash vs. debt$619M vs. $9.0B
Current ratio2.4×Short-term assets for each $1 of bills due within a year
Interest coverage5.3×How many times operating profit covers the interest bill
How we decide
We measure debt in years of earnings (net debt / EBITDA): under 1 is very comfortable, 1 to 3 is manageable, above 3 is heavy. A company that earns less than 3 times its interest bill also counts as weak.
More questions about Royalty Pharma
Data as of Nov 13, 2026.